Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0VI9P
|
||||
| Former ID |
DIB000213
|
||||
| Drug Name |
OPN-305
|
||||
| Synonyms |
OPN-301; TLR-specific mAbs (inflammatory diseases), Opsona; Toll-like receptor specific monoclonal antibodies (inflammatory diseases), Opsona
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Myelodysplastic syndrome [ICD9: 238.7; ICD10:D46] | Phase 2 | [1] | ||
| Company |
Opsona therapeutics
|
||||
| Target and Pathway | |||||
| Target(s) | Toll-like receptor 2 | Target Info | [2] | ||
| KEGG Pathway | Phagosome | ||||
| PI3K-Akt signaling pathway | |||||
| Toll-like receptor signaling pathway | |||||
| Legionellosis | |||||
| Leishmaniasis | |||||
| Chagas disease (American trypanosomiasis) | |||||
| Malaria | |||||
| Toxoplasmosis | |||||
| Amoebiasis | |||||
| Tuberculosis | |||||
| Hepatitis B | |||||
| Measles | |||||
| Herpes simplex infection | |||||
| Proteoglycans in cancer | |||||
| Inflammatory bowel disease (IBD) | |||||
| Rheumatoid arthritis | |||||
| NetPath Pathway | IL4 Signaling Pathway | ||||
| TCR Signaling Pathway | |||||
| PANTHER Pathway | Toll receptor signaling pathway | ||||
| Pathway Interaction Database | Endogenous TLR signaling | ||||
| Reactome | Beta defensins | ||||
| MyD88:Mal cascade initiated on plasma membrane | |||||
| Toll Like Receptor TLR6:TLR2 Cascade | |||||
| MyD88 deficiency (TLR2/4) | |||||
| IRAK4 deficiency (TLR2/4) | |||||
| WikiPathways | Toll-like receptor signaling pathway | ||||
| IL1 and megakaryotyces in obesity | |||||
| Human Complement System | |||||
| Toll-Like Receptors Cascades | |||||
| MyD88:Mal cascade initiated on plasma membrane | |||||
| Defensins | |||||
| Regulation of toll-like receptor signaling pathway | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01794663) Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function. U.S. National Institutes of Health. | ||||
| REF 2 | Treatment with OPN-305, a humanized anti-Toll-Like receptor-2 antibody, reduces myocardial ischemia/reperfusion injury in pigs. Circ Cardiovasc Interv. 2012 Apr;5(2):279-87. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.